Effects of postmenopausal estrogen/progestin replacement therapy on LDL particles; comparison of transdermal and oral treatment regimens

Atherosclerosis

Volumn 122, Issue 2, 1996, Pages 153-162

  Lahdenpera S ^a   Puolakka, J ^b   Pyorala T ^b   Luotola, H ^b   Taskinen, M R ^a,c  

^a UNIVERSITY OF HELSINKI   (Finland)

^b JYVÄSKYLÄ CENTRAL HOSPITAL   (Finland)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Estrogens; LDL subclasses; Lipoproteins; Progestins

Indexed keywords

ESTRADIOL; ESTRADIOL PLUS NORETHISTERONE ACETATE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE ACETATE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG THERAPY; FEMALE; GEL ELECTROPHORESIS; HUMAN; HYPERLIPOPROTEINEMIA; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; PARTICLE SIZE; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRANSDERMAL DRUG ADMINISTRATION; ULTRACENTRIFUGATION;

EID: 0030006988     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/0021-9150(95)05728-5     Document Type: Article

References (44)

1. Bush TL, Barrett-Connor E, Cowan LD, Criqui MH, Wallace RB, Suchindran CM, Tyroler HA, Rifkind BM. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the lipid research clinics program follow-up study. Circulation 1987; 75:1102.
2. Stampfer MJ, Golditz GA, Willett WC, Manson JE, Rosner B, Speizer FE, Hennekens CH. Postmenopausal estrogen therapy and cardiovascular disease. N Engl J Med 1991;325:756.
3. Henderson BE, Paganini-Hill A, Ross RK. Decreased mortality in users of estrogen replacement therapy. Arch Intern Med 1991;151:75.
4. Falkeborn M, Persson I, Adami H-O, Bergström R, Eaker E, Lithell H, Mohsen R, Naessen T. The risk of acute myocardial infarction after oestrogen and oestrogen-progestogen replacement. Br J Obstet Gynecol 1992;99:821.
5. Seed M, Crook D. Post-menopausal hormone replacement therapy, coronary heart disease and plasma lipoproteins. Curr Opin Lipidol 1994;5:48.
6. Walsh BW, Schiff I, Rosner B, Greenberg L, Ravnikar V, Sacks FM. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med 1991;325:1196.
7. Adami S, Rossini M, Zamberlan N, Bertoldo F. Dorizzi R, Lo Cascio V. Long-term effects of transdermal and oral estrogens on serum lipids and lipoproteins in postmenopausal women, Maturitas 1993;11:191.
8. Miller VT, Muesing RA, LaRosa JC, Stoy DB, Fowler SE, Stillman RJ. Quantitative and qualitative changes in lipids, lipoproteins, apolipoprotein A-I, and sex hormone-binding globulin due to two doses of conjugated equine estrogen with and without a progestin. Obstet Gynecol 1994;83:173.
9. Kim CJ, Jang HC, Cho DH, Min YK. Effects of hormone replacement therapy on lipoprotein(a) and lipids in postmenopausal women. Arterioscler Thromb 1994;14:275.
10. Barrett-Connor E, Bush TL. Estrogen and coronary heart disease in women. JAMA 1991;265:1861.
11. Whitehead MI, Hillard TC, Crook D. The role and use of progestogens. Obstet Gynecol 1990;75(Suppl):59.
12. Hickok LR, Toomey C, Speroff L. A comparison of esterified estrogens with and without methyltestosterone: effects on endometrial histology and serum lipoproteins in postmenopausal women. Obstet Gynecol 1993;82:919.
13. Tufekci M, Colak Z, Ozan H, Kimya Y, Aydinlar A. Effect of progestogens on estrogen-induced lipoprotein changes. Eur J Obstet Gynecol Reprod Biol 1993;49:169.
14. Farish E, Fletcher CD, Hart DM, Dagen MM, Parkin DE. Lipoprotein and apolipoprotein levels in postmenopausal women during treatment with norethisterone. Clin Chim Acta 1986;159:147.
15. Hirvonen E, Malkonen N, Manninen V. Effects of different progestogens on lipoproteins during postmenopausal replacement therapy. N Engl J Med 1981;304:562.
16. Fahraeus L, Larsson-Cohn U, Wallentin L. L-norgestrel and progesterone have different influences on plasma lipoproteins. Eur J Clin Invest 1983;13:447.
17. Lobo RA, Effects of hormonal replacement on lipids and lipoproteins in postmenopausal women. J Clin Endocrin Metab 1991;73:925.
18. Fisher WR. Heterogeneity of low density lipoprotein: Manifestations of the physiologic phenomenon in man. Metabolism 1983;32:283.
19. Krauss RM, Burke DJ. Identification of multiple subclasses of plasma low density lipoproteins in normal humans, J Lipid Res 1982;23:97.
20. Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett WS, Kraus RM. Low-density lipoprotein subclass patterns and risk of myocardial infarction. J Am Med Assoc 1988;260:1917.
21. McNamara JR, Campos H, Ordovas JM, Peterson J, Wilson PWF, Schaefer EJ. Effect of gender, age, and lipid status on low density lipoprotein subfraction distribution. Results of the Framingham Offspring Study. Arteriosclerosis 1987;7:483.
22. Austin MA, King MC, Vranizan KM, Newman B, Krauss RM. Inheritance of low-density lipoprotein subclass patterns: results of complex segregation analysis. Am J Hum Genet 1988;43:838.
23. Campos H, McNamara JR, Wilson PWF, Ordivas JM, Schaefer EJ. Differences in low density lipoprotein subfractions and apolipoproteins in premenopausal and postmenopausal women. J Clin Endocrinol Metab 1988;67:30.
24. Campos H, Sacks FM, Walsh BW, Schiff I, O'Hanesian MA, Krauss RM. Differential effects of estrogen on low-density lipoprotein subclasses in healthy postmenopausal women. Metabolism 1993;42:1153.
25. Campos H, Wilson PWF, Jimenez D, McNamara JR, Ordovas J, Schaefer EJ. Differences in apolipoproteins and low-density lipoprotein subfractions in postmenopausal women on and off estrogen therapy: results from the Framingham offspring study. Metabolism 1990;39:1033.
26. Griffin B, Parish E, Walsh D, Barnes J, Caslake M, Shepherd J, Hart D. Response of plasma low density lipoprotein subfractions to oestrogen replacement therapy following surgical menopause. Clin Endocrinol 1993;39:463.
27. Granfone A, Campos H, McNamara JR, Schaefer MM, Lamon-Fava S, Ordovas JM, Schaefer EJ. Effects of estrogen replacement on plasma lipoproteins and apolipoproteins in postmenopausal, dyslipidemic women. Metabolism 1992;41:1193.
28. The Lipid Research Clinics Program Epidemiology Committee: Plasma lipid distributions in selected North American populations: the lipid research clinics program prevalence study. Circulation 1979;60:427.
29. Havel JR, Eder HA, Bragdon JH. Distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 1955;34:1345.
30. Lahdenperä S, Tilly-Kiesi M, Vuorinen-Markkola H, Kuusi T, Taskinen M-R. Effects of gemfibrozil on low-density lipoprotein particle size, density distribution, and composition in patients with type II diabetes. Diabetes Care 1993;16:584.
31. Nichols AV, Krauss RM, Musliner TA. Nondenaturing polyacrylamide gel electrophoresis. In: Segrest JP, Albers JJ (eds.), Plasma Lipoproteins, Methods in Enzymology, Vol. 128. London: Academic Press, 1986;417-431.
32. Margolis J, Kenrick KG. Electrophoresis in polyacrylamide concentration gradient. Biochem Biophys Res Commun 1967;27:68.
33. Polyacrylamide gel electrophoresis; laboratory techniques. Pharmacia, Laboratory Separation Division, Uppsala, Sweden, 1984;16.
34. Huttunen JK, Ehnholm C, Kinnunen PJ, Nikkilä EA. An immunochemical method for selective measurement of two triglyceride lipases in human postheparin plasma. Clin Chim Acta 1975;63:335.
35. Kashyap MR, Hynd BA, Robinson K. A rapid and simple method for measurement of total protein in very low density lipoprotein by the Lowry assay. J Lipid Res 1980;21:491.
36. Hemmilä I, Dakubu S, Mukkala V-M, Siitari H, Lövgren T. Europium as a label in time-resolved immunofluorometric assays. Ann Biochem 1984;137:335.
37. Mertens R, Liedtke RJ, Batjer JD. Evaluation of a radioimmunoassay for estradiol in unextracted serum. Clin Chem 1983;29:1961.
38. Sacks FM, Walsh BW. Sex hormones and lipoprotein metabolism. Curr Opin Lipidol 1994;5.
39. The Writing Group for the PEPI Trial: Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The postmenopausal estrogen/ progestin interventions (PEPI) trial. JAMA 1995;273:199.
40. Miller Bass K, Newschaffer CJ, Klag MJ, Bush TL. Plasma lipoprotein levels 236 as predictors of cardiovascular death in women. Arch Intern Med 1993;153:2209.
41. Windler E, Kovanen PT, Chao YS, Brown MS, Havel RJ, Goldstein JL. The estradiol-stimulated lipoprotein receptor of rat liver. J Biol Chem 1980;255:10464.
42. Griffin BA, Freeman DJ, Tait GW, Thomson J, Caslake MJ, Packard CJ, Shepherd J. Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions: relative contribution of small, dense LDL to coronary heart disease risk. Atherosclerosis 1994;106:241.
43. Kuksis A, Myher JJ, Geher K, Jones GJL, Breckenbridge WC, Feather T, Hewitt D, Little JA. Decreased plasma phosphatidylcholine/free cholesterol ratio is an indicator of risk for ischemic vascular disease. Arteriosclerosis 1982;2:296.
44. Bhatnagar D, Durrington PN, Channon KM, Prais H, Mackness MI. Increased transfer of cholesteryl esters from high density lipoproteins to low density and very low density lipoproteins in patients with angiographic evidence of coronary artery disease. Atherosclerosis 1993;98:25.